Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19766828 | 0.95 | HPGD (0.53) | HPGDALDH1A1HSD17B10KDM4ENPSR1 | |
| SCHEMBL658406 | 0.91 | HPGD (0.53) | HPGDALDH1A1HSD17B10KDM4ENPSR1 | |
| SCHEMBL12939031 | 0.90 | HPGD (0.51) | HPGDALDH1A1HSD17B10KDM4ENPSR1 | |
| SCHEMBL19766834 | 0.90 | HPGD (0.51) | HPGDALDH1A1HSD17B10KDM4ENPSR1 | |
| SCHEMBL658114 | 0.90 | HPGD (0.53) | HPGDALDH1A1HSD17B10KDM4ENPSR1 | |
| SCHEMBL658368 | 0.90 | HPGD (0.53) | HPGDALDH1A1HSD17B10KDM4ENPSR1 | |
| SCHEMBL12939112 | 0.89 | HPGD (0.50) | HPGDALDH1A1HSD17B10KDM4ENPSR1 | |
| SCHEMBL1578000 | 0.89 | HPGD (0.52) | HPGDALDH1A1HSD17B10KDM4ENPSR1 | |
| SCHEMBL2940881 | 0.89 | HPGD (0.52) | HPGDALDH1A1HSD17B10KDM4ENPSR1 | |
| SCHEMBL658116 | 0.88 | HPGD (0.51) | HPGDALDH1A1HSD17B10KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108591-B | Resorcinol derivatives as HSP90 inhibitors | 正大天晴药业集团股份有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-31 | — | — | US | disclosed |
| US-20180009794-A1 | Resorcinol Derivative As HSP90 Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-01-11 | — | — | US | disclosed |
| EP-3248968-A1 | RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2017-11-29 | — | — | EP | disclosed |
| EP-3248968-A1 | RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2017-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | HSP90AB1, HSP90AA1, HSP90AB2P | HPGD 593/4885ALDH1A1 1322/4885HSD17B10 408/4885 |
| US-20180009794-A1 | Resorcinol Derivative As HSP90 Inhibitor | HSP90AB1, HSP90AA1, HSP90AB2P | HPGD 593/4885ALDH1A1 1322/4885HSD17B10 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.